Navigation Links
Ascenta Therapeutics Licenses Cancer Drug Candidates to sanofi-aventis
Date:6/4/2010

ve cancer therapies like these to cancer patients around the world," said Mel Sorensen, M.D., President and Chief Executive Officer of Ascenta Therapeutics. "Restoring tumor suppressor function through the inhibition of the HDM2-p53 interaction offers the potential to control and prevent cancer progression. We are delighted to have sanofi-aventis join us and the University of Michigan in this endeavor to turn exciting science into novel cancer medicines."

About HDM2/p53 Inhibition

Inhibiting the interaction between p53 and HDM2 (human double minute 2, and its murine counterpart, MDM2) is a very promising approach to restoring the natural tumor suppression function of the p53 protein.  The p53 tumor suppressor is a principal mediator of growth arrest, senescence, and apoptosis in response to cellular damage. It is called the "guardian of the genome" because of its role in controlling the cell cycle and monitoring the integrity of the genome. HDM2 is the principal cellular antagonist of p53, acting to limit the p53 growth-suppressive function. Loss of p53 function is involved in 50 percent of cancers, either through mutation, overexpression or amplification of HDM2 in wild-type p53 tumors.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone.  Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).  For more information, please visit: www.san
'/>"/>

SOURCE Ascenta Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. 3SBio and Ascentage Pharma Form Strategic Alliance to Research, Develop and Commercialize Cancer Therapeutics
2. Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting
3. Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models
4. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
5. Scientific and Business Leaders to Discuss Challenges Facing Developers of Pain Therapeutics at Arrowhead's 4th Annual Pain Therapeutics Summit
6. Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h)
7. Talecris Biotherapeutics to Present at the 2010 Citi Investment Research Global Health Care Conference
8. Trius Therapeutics Awarded U.S. Department of Defense Contract to Develop Novel Antibiotics
9. Abviva Announces Further Patent Issuance for Technology Used in Breast Cancer Diagnostics and Therapeutics
10. Fate Therapeutics Expands Scientific Advisory Board to Advance iPSC Technology and Stem Cell Modulator Pipeline
11. Nile Therapeutics Announces Exercise of Over-Allotment Option for Recent Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Boston, MA (PRWEB) January 14, 2014 ... today announces Michelle Detwiler as the new Director of ... current and potential clients as well as iLab sub-teams ... main goal will be to ensure that iLab provides ... offering the most advanced, user-friendly, and high-impact solution in ...
(Date:1/14/2014)... WESTBOROUGH, Mass. , Jan. 14, 2014 ... biotechnology company focused on discovering, developing and ... needs using RNA-targeted technologies, today announced that ... the United States Patent and Trademark Office ... for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, ... management ( SCM ) and sales and operations planning ... gold sponsor of the Biomanufacturing Summit , which ... January 30 – 31, 2014.  At the conference, join ... Chain at Amgen, as she presents ,Supply Chain: Improving ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental products, ... dual arch impressions on its dental blog. , ... entry serves up a list of tips to help dentists ... Dr. David Little as he crafts a porcelain crown using ... as the dual arch dental impression material . ...
Breaking Biology Technology:iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Pressure BioSciences, Inc. (Nasdaq: PBIO ) ... announced that they have entered into a strategic marketing, ... the Agreement, the companies will: (1) share market data, ... certain products at industry trade shows beginning in 2009; ...
... http://www.wellcentive.com ),today announced the launch of two new ... securely and cost-effectively share patient,data within a community ... such as physicians, to easily access patient data ... Connect is a health care technology platform,which receives ...
... NEW YORK, Dec. 11 Delcath Systems, Inc. (Nasdaq: ... its proprietary Percutaneous Hepatic Perfusion ("PHP") System for the treatment ... fifty percent (46 of 92) of patients have been enrolled ... ocular melanoma to the liver. The eleven participating cancer ...
Cached Biology Technology:Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 2Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 3Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 4Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 5WellCentive Launches New Health Information Exchange Platforms 2WellCentive Launches New Health Information Exchange Platforms 3Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 2Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 3
(Date:4/16/2014)... to blame for significant baseline levels of arsenic in ... in the Journal of Environmental Quality . , ... of Ohio showed that every single sample had concentrations ... the U.S. Environmental Protection Agency. The findings should not ... regulatory levels typically are set far below those thought ...
(Date:4/15/2014)... and energy for nearly all life on Earth, yet ... example, little is known about how it is regulated ... we do not know the full list of the ... any organism. , , A type of single-cell green ... subject for photosynthesis research. Despite its importance in the ...
(Date:4/15/2014)... Worcester, Mass. Diana Lados, associate professor ... (WPI) and founding director of the university,s ... two major career achievement awards from leading ... in Detroit, SAE International, a global association ... technical experts in the automotive, aerospace, and ...
Breaking Biology News(10 mins):Significant baseline levels of arsenic found in Ohio soils are due to natural processes 2Significant baseline levels of arsenic found in Ohio soils are due to natural processes 3Significant baseline levels of arsenic found in Ohio soils are due to natural processes 4WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 2WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 3WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 4WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 5
... Jerusalem, November 21, 2010 Research work carried out ... warning in the growing field of the development of ... patients through replacement of diseased or damaged tissues by ... a possible danger of cancerous tissue development in the ...
... Consortium (IVCC) has received $50 million from the Bill ... develop new insecticides for the improved control of mosquitoes ... neglected tropical diseases. IVCC was established ... over five years from the foundation. Since then, ...
... prompts normal cells to transform themselves into cancerous cells? Researchers ... Antonio, have identified factors in the very first step of ... tube. The latter accomplishment was reported Sunday [Nov. 21] in ... The DNA molecule the elegant, twin-stranded necklace of ...
Cached Biology News:Hebrew University research carries cautionary warning for future stem cell applications 2Hebrew University research carries cautionary warning for future stem cell applications 3
Mouse monoclonal antibody raised against a partial recombinant ZNF167. NCBI Entrez Gene ID = ZNF167...
... HDAC8 Regulation of gene expression ... as DNA methylation, ATP-dependent chromatin remodeling, ... which include the dynamic acetylation and ... residues present in the tail of ...
... raised against a partial recombinant ... SLC22A3 (NP_068812, 90 a.a. ... protein with GST tag. ... NM_021977 Protein ...
...
Biology Products: